Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) Operating Expenses (2020 - 2024)

Immuneering (IMRX) has 5 years of Operating Expenses data on record, last reported at $18.6 million in Q4 2024.

  • For Q4 2024, Operating Expenses rose 13.84% year-over-year to $18.6 million; the TTM value through Dec 2024 reached $64.1 million, up 9.69%, while the annual FY2024 figure was $64.1 million, 9.69% up from the prior year.
  • Operating Expenses reached $18.6 million in Q4 2024 per IMRX's latest filing, up from $15.3 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $18.6 million in Q4 2024 and bottomed at $3.9 million in Q2 2020.
  • Average Operating Expenses over 5 years is $11.8 million, with a median of $13.2 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: soared 116.4% in 2021, then grew 4.4% in 2024.
  • A 5-year view of Operating Expenses shows it stood at $6.0 million in 2020, then surged by 84.12% to $11.1 million in 2021, then rose by 26.01% to $14.0 million in 2022, then rose by 16.56% to $16.3 million in 2023, then grew by 13.84% to $18.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $18.6 million in Q4 2024, $15.3 million in Q3 2024, and $14.9 million in Q2 2024.